Sanofi Aktie
WKN: 662283 / ISIN: US80105N1054
27.05.2025 08:32:25
|
Sanofi Buys DR-0201 Myeloid Cell Engager From Dren Bio
(RTTNews) - French pharmaceutical company Sanofi S.A. (SNYNF,SNY) said Tuesday that it completed the acquisition of DR-0201, a targeted bispecific myeloid cell engager. Sanofi acquired DR-0201 from a private clinical-stage biopharmaceutical company Dren Bio, Inc.
Sanofi said DR-0201, which has now been renamed SAR448501, is expected to add to the growth of the company's immunology division in the coming years.
According to the company, DR-0201 was acquired by purchasing Dren 0201, Inc., a Dren Bio affiliate, for an upfront payment of $600 million, with potential milestone payments to the tune of $1.3 billion. Dren Bio will keep on independently developing antibody therapeutics aimed at selectively depleting pathogenic cells, Sanofi added.
Sanofi stated that DR-0201 has shown strong B-cell depletion in both pre-clinical and early clinical studies. The company added that the latest data from research in autoimmune diseases show that the DR-0201 mechanism can help in restoring the adaptive immune system.
The company noted that DR-201 can provide long-lasting, treatment-free remission to patients with difficult-to-treat B-cell-mediated conditions like lupus, where there are too many unfulfilled medical requirements.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Sanofi S.A. (spons. ADRs)mehr Nachrichten
17.10.25 |
Sanofi-Aktie dennoch in Grün: EU-Arzneimittelbehörde lehnt Sanofi-Medikament Rezurock ab (Dow Jones) | |
22.09.25 |
Sanofi-Aktie etwas leichter: Sanofi informiert über Fortschritte bei Dupixent und Tolebrutinib (Dow Jones) | |
10.09.25 |
Sanofi-Aktie fällt: China-Zulassung für Tzield (Dow Jones) | |
22.07.25 |
Sanofi-Aktie stärker: Sanofi expandiert im Impfstoffmarkt durch Übernahme von Vicebio (Dow Jones) | |
20.06.25 |
Dupixent-Erfolg in den USA: Sanofi und Regeneron erhalten erweiterte Zulassung - Aktien gespalten (Dow Jones) | |
02.06.25 |
Aktien von Sanofi in Rot, Blueprint-Aktie mit Kurssprung: Sanofi stärkt Onkologie-Portfolio mit Blueprint-Übernahme (Dow Jones) | |
30.05.25 |
Itepekimab in der Studie: Sanofi berichtet von uneinheitlicher Wirksamkeit - Aktie verliert stark (finanzen.at) | |
22.05.25 |
Sanofi-Aktie schwächer: Konzern kauft Vigil Neuroscience (Dow Jones) |
Analysen zu Sanofi S.A. (spons. ADRs)mehr Analysen
Aktien in diesem Artikel
Sanofi S.A. (spons. ADRs) | 42,80 | 0,00% |
|
Sanofi S.A. | 86,38 | 0,57% |
|